PMPal Miheller

Pal Miheller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pal Miheller has a total of 286 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study

    by Péter Bacsur, Daniel Shaham, Zuzana Serclova, Tamás Resál, Bernadett Farkas, Patrícia Sarlós, Pál Miheller, Nitsan Maharshak, Meir Zemel, Ariella Bar‐Gil Shitrit, et al.

    Background: Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose‐derived mesenchymal stem cell treatment are contradicting, and real‐world evidence is lacking.Aims: To examine the usability of darvadstrocel therapy in managing perianal CD.Methods: We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression.Results: Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported.Conclusion: Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success.


  • Open Access

    Effect of obesity on postoperative complications in ulcerative colitis: A systematic review and meta‐analysis

    by L. M. Tóth, H. Székely, A. Rancz, Á. Zolcsák, M. D. Sárközi, S. Ábrahám, L. Földvári‐Nagy, B. Erőss, P. Hegyi, P. Miheller

    Background: The prevalence of ulcerative colitis (UC) is around 200/100 000 people. Colectomy is required in 7.5%–40% of patients and 58.8%–94% of these operations are elective. Approximately one in two adults with UC are overweight or obese.Objective: Our aim was to compare postoperative complications between obese (defined by a body mass index (BMI) over 30 kg/m2) and non‐obese UC patients who underwent total proctocolectomy with ileal pouch‐anal anastomosis (IPAA).Methods: Our preregistered protocol can be found on PROSPERO (CRD42022377761). We conducted our search in three databases on the 26th of November 2022. PRISMA 2020 guideline and the Cochrane Handbook were applied. We used the GRADEpro program and the QUIPS tool. We applied a random‐effects model to pool effect sizes. We included cohort and case–control studies investigating UC patients undergoing colectomy with IPAA and reported information on postoperative complications in obese and non‐obese patients. We used mean difference (MD) for continuous variables and calculated odds ratio (OR) with a 95% confidence interval (CI) for dichotomous variables.Results: Of the 6870 hits of our systematic search, we included three retrospective cohort studies for analyses involving 4929 patients in our research. Neither the incidence of complications at 30 days after surgery [OR = 1.08; CI: 0.65–1.79] nor the incidence of septic complications [OR = 1.11; CI: 0.85–1.46] had any clinical relevance, except for the length of hospital stay [MD = 0.36; CI:0.04–0.69]. When we assessed the risk of bias, we found that most of the aspects examined had a moderate overall risk. Our results have very low certainty of evidence.Conclusions and Relevance: Our findings suggest that obesity defined as BMI over 30 kg/m2 may not associated with an increased risk of higher rates of overall postoperative complications compared to non‐obese patients. Obesity with a cut‐off value of 30 kg/m2 does not appear to be a primary reason for prehabilitation.


  • Open Access

    Hypocalcemia on Admission Is a Predictor of Disease Progression in COVID-19 Patients with Cirrhosis: A Multicenter Study in Hungary

    by Bálint Drácz, Veronika Müller, István Takács, Krisztina Hagymási, Elek Dinya, Pál Miheller, Attila Szijártó, Klára Werling

    Hypocalcemia is a common condition in liver cirrhosis and is associated with the severity of SARS-CoV-2 infection. However, there is a lack of data demonstrating the prognostic value of hypocalcemia in COVID-19 patients with cirrhosis. This study aimed to evaluate the prognostic value of hypocalcemia for COVID-19 severity, mortality and its associations with abnormal liver function parameters. We selected 451 COVID-19 patients in this retrospective study and compared the laboratory findings of 52 COVID-19 patients with cirrhosis to those of 399 COVID-19 patients without cirrhosis. Laboratory tests measuring albumin-corrected total serum calcium were performed on admission, and the levels were monitored during hospitalization. The total serum calcium levels were significantly lower in cirrhosis cases (2.16 mmol/L) compared to those without cirrhosis (2.32 mmol/L). Multivariate analysis showed that hypocalcemia in COVID-19 patients with cirrhosis was a significant predictor of in-hospital mortality, with an OR of 4.871 (p < 0.05; 95% CI 1.566–15.146). ROC analysis showed the AUC value of total serum calcium was 0.818 (95% CI 0.683–0.953, p < 0.05), with a sensitivity of 88.3% and a specificity of 75%. The total serum calcium levels showed a significant negative correlation with the Child–Turcette–Pugh score (r = −0.400, p < 0.05). Hypocalcemia on admission was a significant prognostic factor of disease progression in COVID-19 patients with cirrhosis.


  • Open Access

    Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study

    by Bálint Drácz, Veronika Müller, István Takács, Krisztina Hagymási, Elek Dinya, Pál Miheller, Attila Szijártó, Klára Werling

    Patients with cirrhosis are vulnerable to hepatic decompensation events and death following COVID-19 infection. Therefore, primary vaccination with COVID-19 vaccines is fundamental to reducing the risk of COVID-19 related deaths in patients with cirrhosis. However, limited data are available about the effectiveness of mRNA vaccines compared to other vaccines. The aim of our study was to investigate the efficacy of mRNA vaccines versus other vaccines in cirrhosis. In this retrospective study, we compared clinical characteristics and vaccine effectiveness of 399 COVID-19 patients without cirrhosis (GROUP A) to 52 COVID-19 patients with cirrhosis (GROUP B). 54 hospitalised cirrhosis controls without COVID-19 (GROUP C) were randomly sampled 1:1 and matched by gender and age. Of the cirrhosis cases, we found no difference (p = 0.76) in mortality rates in controls without COVID-19 (11.8%) compared to those with COVID-19 (9.6%). However, COVID-19 patients with cirrhosis were associated with higher rates of worsening hepatic encephalopathy, ascites and esophageal varices. Patients with cirrhosis receiving mRNA vaccines had significantly better survival rates compared to viral vector or inactivated vaccines. Primary vaccination with the BNT162b2 vaccine was the most effective in preventing acute hepatic decompensating events, COVID-19 infection requiring hospital admission and in-hospital mortality.


  • Open Access

    Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters

    by Éva Anna Piros, Ákos Szabó, Fanni Rencz, Valentin Brodszky, Norbert Wikonkál, Pál Miheller, Miklós Horváth, Péter Holló

    BACKGROUND: Psoriasis is frequently accompanied by metabolic syndrome. Effect of anti-tumor necrosis factor therapies on increases in body weight is well-known. Data on the effects of interleukin-17 inhibitors are limited. Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients. METHODS: Thirty-five severe psoriatic patients were enrolled. Twenty-two received secukinumab and 13 received ixekizumab as their 2nd-or 3rd-line biological treatment. Before treatment initiation and 6 months later, laboratory examinations measuring metabolic and inflammatory panels and body composition analyses were performed. RESULTS: After 6 months, a significant reduction was observed in psoriasis area severity index (p < 0.001) from 18 to 0, in c-reactive protein (p < 0.001) from 6.6 to 4.00 mg/L, in low-density lipoprotein-cholesterol (p = 0.004) from 3.69 to 3.19 mmol/L, and an improvement in high-density lipoprotein-cholesterol (p = 0.022) from 1.31 to 1.40 mmol/L. Median baseline body mass index was 32.80 kg/m2. The body composition parameters did not show any significant changes. CONCLUSIONS: Anti-interleukin-17 therapy of severe psoriatic patients does not cause significant changes in body composition parameters. Improvements in the lipid and inflammatory parameters might have a beneficial effect on patients’ cardiometabolic status. This effect might be detectable in high-risk obese psoriatic patients.


  • DESCRIPTIVE ANALYSIS OF 159 CONSECUTIVE CAPSULE ENDOSCOPIES AT A REFERRAL CENTER IN BUDAPEST

    by D Lippai, M Fazekas, R Krenacs, P Miheller, K Mullner, L Madacsy, Z Tulassay

    Aims: To evaluate characteristics of patients visiting a referral center for capsule endoscopy (CE) during 2014 – 2017. Methods: MiroCam was used for diagnosis of gastrointestinal bleeding and evaluated by two physicians. Including criteria was negative bleeding in endoscopy examination within 3 months. Detailed questionnaire was applied. Results: 159 CE were performed for 156 patients (73 males, 83 females). Age-range was 17 – 86 (mean: 60). BMI-varied between 16.6 and 49 (mean: 27). H. pylori was tested in 46% of patients and amongst 19% positive. Transfusion of 426 units was reported in 58% of cases. Six cases had bleeding disorder. Regular NSAID users were 18%. Anticoagulant drugs were taken by 52 (32%) cases. Mean duration of CE was 543 minutes (ranged: 138 – 720). Mean passage time in stomach and small intestine (SI) was 38 and 270 minutes. Gastric lesions included 17 active bleeding, 2 ulcers, 6 telangiectasias. CE of small intestine showed 65% hyperemia, 82% doted erosions, 18% spotted erosions, 18% ulcers, 28% telangiectasias, 33% angiodysplasias, 18% active bleedings, 30% lymphangiectasis, 31% polypoid lesions, and 4% tumor-like lesions. Cecal images showed 4 active bleedings, 2 ulcers, 12 telangiectasias and angiodysplasias. Capsule regurgitation from stomach to duodenum and from coecum to ileum was noted in 15 (9%) and 3 (2%). Concordant gastric vascular lesions coexisted in 50% with SI lesions, whereas all vascular lesions in colon coexisted with SI lesions. NSAID use was associated with spotted erosion and ulcer in SI (p = 0.028). H. pylori, smoking, alcohol, anticoagulant use and BMI were not associated with SI bleeding. In follow-up data (31%), death incidence was higher among those with bleeding or ulcer in SI detected by CE (p = 0.003). Conclusions: Vascular lesions were the most common observed abnormalities of small intestine in our series. High proportion of mortality among ulcerative lesions in CE highlights the importance of post-capsule follow-up.

  • DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease

    by R Bor, F Klaudia, P Miheller, K Palatka, T Szamosi, Á Vincze, M Rutka, K Szántó, A Bálint, Z Szepes, et al.

    Vedolizumab (VDZ) is the first gut-specific monoclonal antibody alternative to anti-tumour necrosis factor alpha (anti-TNF-alpha) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD). It has been registered since 2016 in Hungary. All newly initiated VDZ therapy was individualised, it should be approved by the steering committee of five Hungarian IBD specialists. Aims of our non-interventional retrospective study to assess the efficacy of induction VDZ therapy on clinical and endoscopic activity in moderate or severe active IBD with previous anti-TNF failure or intolerance in real-life setting. Anti-TNF-alpha therapy intolerant IBD patients who received induction VDZ therapy were enrolled between July 2016 and July 2017 in Hungary. The therapeutic response was assessed based on the changes of clinical (Crohn’s Disease Activity Index [CDAI], Mayo score) and endoscopic (Simple Endoscopic Score for Crohn Disease [SES-CD], endoscopic Mayo score) scores. Clinical response was defined as >3 points decrease in the total Mayo score or >100 decrease in CDAI score from baseline. Remission was defined as Mayo score ≤2, with no individual subscores >1, or as CDAI score ≤150. Mucosal healing was defined as Mayo endoscopic subscore ≤1 or as SES CD score ≤4. 40 Crohn’s disease (CD) and 52 ulcerative colitis (UC) patients received VDZ induction therapy after anti-TNF failure or intolerance. The mean age was 39.3 years (range 18–79; median 39) and the average disease duration was 11.4 years (range 1–36; median 10). At the baseline the mean CDAI and SES-CD were 306 (range 190–430; median: 316) and 19.2 (range 6–37; median 18) in the CD group and mean Mayo and eMayo score were 9.7 (range 5–12; median 10) and 2.75 (range 2–3; median 3) in the UC group. Extra intestinal manifestations were occurred in 26 patients (28.3%), and in 7 cases (7.6%) the IDB was associated with primary sclerosing cholangitis. 26 (65.0%) CD and 44 (84.6%) UC patients showed clinical response on the induction VDZ therapy. The number of patients with clinical remission was 21 (52.5%) in the CD and 24 (46.2%) in the UC subgroup. Rate of steroid-free remission was 42.5% (n = 17) in CD and 26.9% (n = 14) in UC. Steroids could be stopped in 54.7% of the patients receiving systemic corticosteroids at inclusion. Mucosal healing at week 14 was achieved in 8 (20.0%) and CD and 28 (53.8%) UC patients. Our results suggest that induction VDZ therapy is effective and it is a safe therapeutic option in anti-TNF-alpha failure or intolerant IBD patients with moderate or severe disease activity. Mucosal healing was achievable in every second UC and in every fifth CD patients by the end of the induction treatment in this difficult-to-treat population.


  • Open Access

    P840 IBD-related malignancies and mortalities observed in 2015–2017: 3 years’ results from the prospective nationwide Hungarian registry

    by T Molnar, F Nagy, P Fritz, L Lakatos, Z Erdélyi, P Miheller, T Szamosi, E Schafer, A Vincze, P Sarlós, et al.

    Inflammatory bowel diseases (IBD-Crohn’s disease (CD); ulcerative colitis (UC)) are lifelong inflammatory conditions of the gastrointestinal tract. Early literature suggests the overall excess mortality burden was negligible in UC and only marginally increased in CD compared with the general population. Emerging data are challenging earlier perceptions of IBD-associated mortality. The aim of our nationwide registry was to prospectively collect IBD-related mortalities and all types of malignancies diagnosed in the Hungarian IBD population. Data on all death and malignancies developed between January 2015 and December 2017 in IBD patients were recorded. Each member of the Hungarian Society of Gastroenterology were prospectively interviewed 3 monthly by personal emails to report both death and malignancies observed in their patient population. Demographic and clinical data including previous immunosuppressive and biological therapy were also collected. Our definition of death possibly related with IBD: (1) cause of death is a consequence of a complication of IBD, (2) a consequence of IBD-related malignancy, or (3) a consequence of an infection during immunosuppressive therapy. Sixty-eight newly diagnosed malignancies were reported. More than half of the cancers were CRC (n = 36), one of them had pouch cancer previously colectomized because of sigmoid tumour. Other malignant diseases were registered in 32 cases. Twenty-eight of the 36 CRC cases were associated with UC, 60% with pancolitis. Twenty of the 36 cases were located in the rectosigmoid region, 2 had multiple localisation, 13 were located in the colon and one patient had pouch cancer after an IPAA procedure had performed because of UC-associated sigmoid tumour. 23 deaths were reported during the examined period. Eleven fatal cases were possibly related to IBD: 5 infection-related cases: 3 septic shock, 1 interstitial pneumonitis, 1 meningitis; 3 cancer-related cases: 1 rectal and 1 pouch cancer, 1 pancreatic cancer (associated with PSC); 3 disease-related: 1 haemorrhagic shock, 1 intestinal perforation and 1 treatment refractory, serious malnutrition. Age of death was significantly lower in case of IBD-related mortality compared with the other patients and general population (41.6 vs. 64.3 vs. 73.4 (data from Central Statistical Office 2013, Hungary) years, p < 0.05). The most frequently observed IBD-related malignancy is CRC, which can be multifocal and mainly involve the distal part of the colorectum typically in UC patients with pancolitis and chronic activity. Malignancy and septic complications were the leader causes of IBD-related mortality characterised by earlier death than in the rest and in the non-IBD population.

  • Open Access

    Celiac disease association with other autoimmune disorders: Three case reports

    by Dorottya Kocsis, Melinda Csaplár, Eszter Jócsák, Péter Pák, Zsuzsanna Tóth, Pál Miheller, László Herszényi, Miklós Tóth, Zsolt Tulassay, Mark Juhasz

    Background: A 15 year period retrospective study at our celiac centre (Semmelweis University 2nd Department of Internal Medicine) has found, that 91 out of 248 coeliac patients (20 male, 71 female) also suffered from at least one autoimmune disease associated with celiac disease. The objective of the following case reports is to demonstrate the protean faces of celiac disease and the association tendency with other autoimmune disorders. Case presentation: 34-years old male patients presented with peripheral neuropathy. Results of electrophysiological studies were normal. Immunpanel examination was detected elevated tissue Transglutaminase antibodies levels. Duodenal biopsy revealed villous atrophy. Patient was started on strict gluten free diet and one year later he had almost complete recovery. 46-years-old male diagnosed with Dermatitis herpetiformis Duhring and celiac disease 20-years ago. In the last few years in spite of the gluten-free diet, he newly presented intestinal symptoms and chronic iron deficiency anaemia. The control tissue Transglutaminase antibodies, and duodenal biopsies were negative. Colonoscopy found inflammation in terminal ileum; video capsule endoscopy detected multiple ulcerative lesions in whole small bowel. The results confirmed the diagnosis of Crohn’s disease. A 22-years old female patient diagnosed with celiac disease during the puerperium. The patient had muscles weakness, swallowing dysfunction, diplopia and generalized fatigue too. Muscle biopsies were normal. The electromyography was specific to myasthenia gravis. Computed tomography found thymus persistent. After tymectomy she showed good clinical response to immunosuppressant and cholinesterase inhibitor therapy. Conclusion: Autoimmune disorders have often been associated with celiac disease.